Chronic Total Occlusion (CTO) Data
“If you look at what interventional cardiologists are doing today in the cardiac cath lab, it’s nowhere near the same as it was 5 years ago. Five years ago we were not doing CTOs to the degree we’re doing today.”
— David Rizik, MD
For years patients with chronic total occlusions (CTO) posed a challenge for physicians implanting bare metal stents (BMS), since restenosis was common in this population.1 First generation drug-eluting stents (DES) improved results, yet the risk of very late stent thrombosis (ST) remained.
Now, XIENCE is designed to offer peak performance in increasingly complex lesions such as CTOs—with a ST rate of 0.7%.2
PRISON IV Trial Examines XIENCE for CTO
The Orsiro hybrid sirolimus-eluting stent (SES), a biodegradable polymer DES (BP-DES), was designed to overcome possible drawbacks of earlier generations of DES. The PRISON IV trial—a prospective, multicenter randomized trial—looked at XIENCE vs Orsiro in CTO patients.2
XIENCE Outperforms Orsiro in CTOs—Lack of Non-Inferiority for SES2
"We chose the most reputable stent, . . . XIENCE, to challenge the novel Orsiro sirolimus-eluting stent [SES] in this complex lesion subset. . . . This trial failed to show non-inferiority of the SES. . . . Furthermore, the rate of binary restenosis was statistically significantly higher with the SES [Orsiro]."
— Koen Teeuwen, MD, PRISON IV Trial2
PRISON Primary Endpoint: In-Segment Late Lumen Loss (mm) at 9 Months
Primary Endpoint: In Segment Late Lumen Loss at 9 months (mm)
XIENCE Outperforms Orsiro in CTOs—Restenosis and TLR2
In examining XIENCE compared to Orsiro, the Orsiro arm revealed:
- Significantly higher binary restenosis
- Higher clinically driven target lesion revascularization (TLR)